# Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

> **NCT07007728** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 54 (estimated)

## Conditions studied

- Colorectal Neoplasms
- Secondary Malignant Neoplasm of Liver

## Interventions

- **DRUG:** Iparomlimab/Tuvonralimab
- **DRUG:** Bevacizumab + CAPEOX
- **PROCEDURE:** Surgical resection ± ablation or stereotactic radiotherapy (if applicable)

## Key facts

- **NCT ID:** NCT07007728
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07007728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07007728, "Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07007728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*